No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 32 | 14 | 27 | 6 | 4 | 10 | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | -171 | -92 | 28 | -96 | -126 | -251 | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.